INNODIA主方案:用于评估儿童、青少年和成人新诊断1型糖尿病研究性药品
INNODIA联盟基于自然史研究建立泛欧洲基础设施,前瞻性评估新诊断1型糖尿病患者的临床数据并集中收集样本,以确定β细胞功能下降速率和新型生物标志物。本文介绍主方案,旨在改进评估单药或联合研究性药品的2期研究实施,提供标准化疗效与安全性评估、机制数据收集、适应性设计和共享对照组,以及更好理解终点变异以优化样本量计算和基线分层。
要点
- 主方案基于INNODIA自然史研究,用于评估新诊断1型糖尿病的研究性药品。
- 提供标准化疗效与安全性评估、可比较的机制数据收集。
- 支持适应性设计和共享对照组评估联合治疗。
核心结论
- 主方案可改进评估单药或联合研究性药品的2期研究实施,以预防或逆转新诊断1型糖尿病患者的β细胞功能下降。
研究设计与样本
- 基于INNODIA自然史研究骨干开发的主方案,利用泛欧洲基础设施中经验证的中心前瞻性评估临床数据并集中收集临床样本。
主要发现
- 许多研究性药品在2期研究中显示潜在疗效,但后续3期研究很少证实这些获益。
- 当前2期药物开发受限于药物剂量评估不佳和缺乏理解研究性药品可变反应的机制数据。
- 识别可在基线更稳健分层参与者的生物标志物进展缓慢。
关键数值与推荐
- 主方案提供标准化疗效与安全性评估。
- 主方案提供可比较的机制数据收集。
- 主方案提供纳入适应性设计和在联合治疗评估中使用共享对照组的机会。
- 主方案提供更好理解终点变异的好处,以确保更稳健的样本量计算和利用现有及新型生物标志物进行未来基线分层。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell function and identify novel biomarkers, which could be used for future stratification of phase 2 clinical trials. METHODS: In this context, we have developed a Master Protocol, based on the "backbone" of the INNODIA natural history study, which we believe could improve the delivery of phase 2 studies exploring the use of single or combinations of Investigational Medicinal Products (IMPs), designed to prevent or reverse declines in beta-cell function in individuals with newly diagnosed type 1 diabetes. Although many IMPs have demonstrated potential efficacy in phase 2 studies, few subsequent phase 3 studies have confirmed these benefits. Currently, phase 2 drug development for this indication is limited by poor evaluation of drug dosage and lack of mechanistic data to understand variable responses to the IMPs. Identification of biomarkers which might permit more robust stratification of participants at baseline has been slow. DISCUSSION: The Master Protocol provides (1) standardised assessment of efficacy and safety, (2) comparable collection of mechanistic data, (3) the opportunity to include adaptive designs and the use of shared control groups in the evaluation of combination therapies, and (4) benefits of greater understanding of endpoint variation to ensure more robust sample size calculations and future baseline stratification using existing and novel biomarkers.
引用
- Dunger DB, Bruggraber SFA, Mander AP, et al. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes. Trials. 2022. PMID: 35585600. doi:10.1186/s13063-022-06259-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。